COVID-19 patients who are vaccinated -- and were hospitalized with reduced kidney function -- had better outcomes than unvaccinated patients, a new study finds.

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated patients with the same condition, new research suggests. The study found ...

The American College of Obstetricians and Gynecologists is urging insurers to continue covering vaccinations during pregnancy in an open letter signed by 30 prominent professional health organizations ...

Some appointees hold some of Kennedy’s more critical views on vaccines, while other picks appear to be olive branches to ...

BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in all-stock transaction that values the acquired biotech at ...

Senior Biden Food and Drug Administration (FDA) officials spent weeks casting doubt on reports of cardiac risks associated with the ...

U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it was "plagued ...